Aratana Therapeutics Inc (PETX) Releases Earnings Results, Misses Expectations By $-0.09 EPS

Aratana Therapeutics Inc (PETX) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.52 earnings per share for the quarter, missing the analyst consensus estimate by $-0.09. Analysts had a consensus of $-0.43. The company posted revenue of $.17 million in the period, compared to analysts expectations of $.13 million. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.

Many Wall Street Analysts have commented on Aratana Therapeutics Inc. Shares were Reiterated by Stifel on Mar 16, 2016 to “Buy” and Lowered the Price Target to $ 11 from a previous price target of $12 .

Aratana Therapeutics Inc closed down -0.3 points or -5.03% at $5.67 with 6,65,190 shares getting traded on Wednesday. Post opening the session at $5.85, the shares hit an intraday low of $5.54 and an intraday high of $6.11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Feb 2, 2016, Craig A Tooman (CHIEF FINANCIAL OFFICER) sold 2,806 shares at $3.36 per share price. According to the SEC, on Jul 17, 2015, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $17.06 per share price. On Apr 28, 2015, Linda Rhodes (CHIEF SCIENTIFIC OFFICER) sold 15,000 shares at $15.28 per share price, according to the Form-4 filing with the securities and exchange commission.

Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Aratana Therapeutics Inc

Leave a Reply

Aratana Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aratana Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.